Overview

AZD0585 Phase III Long-term Study in Japan

Status:
Completed
Trial end date:
2017-03-11
Target enrollment:
Participant gender:
Summary
This study is a randomised, double-blind phase III long-term study to evaluate efficacy and safety of 12 weeks and 52 weeks of AZD0585 administration compared to placebo in patients with hyperlipidemia accompanied by hypertriglyceridemia .
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca